# US 8,771,746 B2 · Colloidal suspensions comprising a therapeutic agent and squalene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,746 B2
- Document ID: US8771746B2
- Status: Granted
- Kind: B2
- Application number: 13/146,618
- Filed: 2009-06-18
- Published: 2012-08-16
- Granted: 2014-07-08
- Earliest claimed: 2008-06-19
- Assignees: Otonomy, Inc.
- Applicants: John Vinton Schloss; Thomas Jay Lobl
- Inventors: John Vinton Schloss; Thomas Jay Lobl
- Web page: https://patentgrep.com/patent/US8771746B2

## CPC

- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Colloidal suspensions comprising a therapeutic agent and squalene. Squalene binds to certain compounds, such as gacyclidine, much more tightly than other drug carriers, such as polylactic glycolic acid. Including squalene in the particulate phase sequesters the therapeutic agent and provides superior stability at room or body temperature.

## Claims

### Claim 1

A colloidal aqueous suspension, comprising nanoparticles that comprise squalene and a therapeutic agent selected from the group consisting of a phencyclidine analog, ifenprodil, traxoprodil, (±)-(R,S)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propanol, and carbamathione.

### Claim 2 (depends on 1)

The colloidal suspension of claim 1, wherein the therapeutic agent is a phenycyclidine analog and the phenycyclidine analog is selected from the group consisting of gacyclidine and ketamine.

### Claim 3 (depends on 1)

The colloidal suspension of claim 1, further comprising an amphipathic excipient.